How much dividend does Biontech pay?
Over the past 12 months, Biontech paid a dividend of 2.13 EUR . This corresponds to a dividend yield of about 2 %. For the coming 12 months, Biontech is expected to pay a dividend of 0 EUR.
Biontech Dividend 2024
Biontech Dividend
0 EUR
Biontech Dividend yield
2 %
Ticker
BNTX
ISIN
US09075V1026
WKN
A2PSR2
How much dividend does Biontech 2024 pay?
According to the latest status from October 2024, Biontech paid a total of 0 EUR per share in dividends within the last 12 months. With the current Biontech price of 106.65 EUR, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.
| 2 % Dividend Yield | = |
|
Historical Biontech Dividends
A dividend is paid times per year. Last year, the payout months were and .
| Paydate | Dividend |
|---|---|
| 7/2/2022 | 2.13 |
1
Biontech dividend history and estimates US09075V1026 · A2PSR2
In 2023, Biontech paid a dividend amounting to 0 EUR. Dividend means that Biontech distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Biontech provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Biontech’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Biontech's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Biontech Dividend History
| Date | Biontech Dividend |
|---|---|
| 2022 | 2.13 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2017 | 0 EUR | 0 EUR |
| 2018 | 0 EUR | 0 EUR |
| 2019 | 0 EUR | 0 EUR |
| 2020 | 0 EUR | 0 EUR |
| 2021 | 0 EUR | 0 EUR |
| 2022 | 2.13 EUR | 0 EUR |
| 2023 | 0 EUR | 0 EUR |
| 2024e | 0 EUR | 0 EUR |
| 2025e | 0 EUR | 0 EUR |
| 2026e | 0 EUR | 0 EUR |
| 2027e | 0 EUR | 0 EUR |
| 2028e | 0 EUR | 0 EUR |
| 2029e | 0 EUR | 0 EUR |
Is the Biontech Dividend Safe?
Biontech has been increasing the dividend for 1 years.
Over the past 7 years, Biontech has increased it by an annual 0 %.
Over a five-year period, the distribution increased by 0%.
Analysts expect a Dividend Cut of -100% for the current fiscal year.
Biontech dividend payout ratio US09075V1026 · A2PSR2
In 2023, Biontech had a payout ratio of 5.65%. The payout ratio indicates the percentage of the company's profits that Biontech distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Biontech represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Biontech could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Biontech's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Biontech Payout Ratio History
| Date | Biontech Payout ratio |
|---|---|
| 2029e | 5.65 % |
| 2028e | 5.65 % |
| 2027e | 5.65 % |
| 2026e | 5.65 % |
| 2025e | 5.65 % |
| 2024e | 5.65 % |
| 2023 | 5.65 % |
| 2022 | 5.65 % |
| 2021 | 5.65 % |
| 2020 | 5.65 % |
| 2019 | 5.65 % |
| 2018 | 5.65 % |
| 2017 | 5.65 % |
| Payout ratio | |
|---|---|
| 2017 | 5.65 % |
| 2018 | 5.65 % |
| 2019 | 5.65 % |
| 2020 | 5.65 % |
| 2021 | 5.65 % |
| 2022 | 5.65 % |
| 2023 | 5.65 % |
| 2024e | 5.65 % |
| 2025e | 5.65 % |
| 2026e | 5.65 % |
| 2027e | 5.65 % |
| 2028e | 5.65 % |
| 2029e | 5.65 % |
Dividend Details
Understanding Biontech's Dividend Distributions
Biontech’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Year-to-Year Comparison
Examining Biontech's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Impact on Investments
Biontech's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Interpreting Dividend Fluctuations
Changes in Biontech’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Biontech Aktienanalyse
What does Biontech do?
BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech is one of the most popular companies on Eulerpool.com.Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biontech stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Frequently Asked Questions about Biontech stock
What is the dividend yield of Biontech?
The current dividend yield of Biontech is 2 %.
When does Biontech pay dividends?
Biontech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biontech?
Biontech paid dividends every year for the past 2 years.
What is the dividend of Biontech?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biontech located?
Biontech is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biontech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biontech from 6/17/2022 amounting to 2.132 EUR, you needed to have the stock in your portfolio before the ex-date on 6/2/2022.
When did Biontech pay the last dividend?
The last dividend was paid out on 6/17/2022.
What was the dividend of Biontech in the year 2023?
In the year 2023, Biontech distributed 2.132 EUR as dividends.
In which currency does Biontech pay out the dividend?
The dividends of Biontech are distributed in EUR.
Andere Kennzahlen von Biontech
Our stock analysis for Biontech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biontech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
